Purpose: The aim of this article was to determine reliability of the Test of Infant Motor Performance (TIMP) in infants with spinal muscular atrophy, type I (SMA-I).
Methods: Interrater reliability training was undertaken by 17 physical therapist evaluators using 6 infants with hypotonia and weakness (5 videotaped, 1 live). Eight trained evaluators then conducted a test-retest reliability study at their own center, performing 2 tests approximately 1 month apart on each of 11 infants with genetically confirmed SMA-I (5 boys, 6 girls; age range 37–501 days; 3 on pulmonary support).
Results: The interrater reliability training session had an overall weighted Κ of 0.61 (95% confidence interval 0.59–0.63). For the test-retest reliability study, the intraclass correlation coefficient for the TIMP Total Score was 0.85 (95% confidence interval: 0.54–0.96). The test scores were not significantly different between the 2 sessions (Bradley-Blackwood test was nonsignificant).
Conclusion: TIMP scores can be reliably obtained in infants with SMA-I.
This multicenter study demonstrates that TIMP scores can be reliably obtained in infants with SMA-I.
Division of Neurology (R.S.F.) and Department of Physical Therapy (A.M.G.), The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Departments of Neurology and Pediatrics (R.S.F.), The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Department of Clinical Science (L.S.H.) and Departments of Neurology and Pediatrics (S.T.I.), University of Texas Southwestern Medical Center, Dallas, Texas; Department of Physical Therapy (H.O., L.N., S.R.C.) and Department of Neurology (S.T.I.), Texas Scottish Rite Hospital for Children, Dallas, Texas; and Department of Physical Therapy (S.K.C.), The University of Illinois at Chicago, Chicago, Illinois
Address correspondence to: Richard S. Finkel, MD, Division of Neurology, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104. E-mail: email@example.com
Grant support: Supported by the AmSMART trial (NIH RO1 NS39327), The Children's Hospital of Philadelphia CTRC (NIH MO1-RR-000240), and The Families of SMA (Project Cure grant to R.S.F.).